The Reynolds Risk Score is a clinical risk prediction algorithm rather than a single blood analyte. It integrates demographic and physiologic inputs (for example age, sex, blood pressure, cholesterol measures), family history of premature heart events, and an inflammatory biomarker (hs‑CRP) to produce a probabilistic estimate of short‑term cardiovascular risk. Developed to improve risk classification beyond older models, this score was validated in large prospective cohorts and is used as a tool to reclassify individuals whose risk is uncertain by standard calculators. Its core function is to translate multiple, interacting inputs into a single, interpretable risk estimate that reflects the combined contribution of lipid burden, hemodynamic load, family predisposition, and systemic inflammation.

Higher Reynolds Risk Scores are associated with a greater estimated probability of near‑term cardiovascular events; in population studies higher scores align with patterns of adverse lipids, elevated blood pressure, positive family history, and raised inflammation (hs‑CRP). Lower scores are associated with a lower estimated probability and typically occur when traditional risk factors and inflammatory signals are favorable. These patterns are probabilistic associations, not diagnoses. Interpretation is most informative when compared with other Cardio Zoomer domains—lipid particle measures, inflammatory and oxidative stress markers, metabolic indicators, and genetic risk—to reveal which biological pathways may be driving the score.

Cardio Zoomer includes the Reynolds Risk Score to combine inflammatory, clinical, and family‑history signals into a single, actionable risk estimate. It helps clinicians see how inflammation and traditional risk factors interact with advanced lipid and genetic data, aiding prioritization of further evaluation and personalized prevention planning.